Cytomegalovirus vectors and methods of use
By infecting mammalian cells by recombinant human cytomegalovirus vectors and producing and releasing viral vectors, the problems of complexity and inefficient treatment of CAR T cell generation in the prior art are solved, and immune cell editing and disease-targeted treatment are achieved in vivo.
Patent Information
- Application Number
- CN202380026084.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-07
- Filing Date
- 2023-01-04
- Publication Date
- 2024-11-08
AI Technical Summary
The existing CAR T cell generation methods are complex and multi-step, making it difficult to achieve single step in vivo immune cell editing, and are limited in treatment efficiency for cancer and infectious diseases.
Recombinant human cytomegalovirus (hCMV) vector, including the genome and packaging polypeptide encoding viral gene transfer vector, can infect mammalian cells, produce and release viral vectors, guide immune cells to express therapeutic polypeptides or antigen receptors, and induce immune responses. Targeting cancer and infectious diseases.
It achieves simple and efficient editing of immune cells in vivo, enhances the therapeutic effect on cancer and infectious diseases, and targets and destroys disease cells by inducing an immune response to specific antigens.
Smart Images

Figure HDA0005031628150000011 
Figure HDA0005031628150000021 
Figure HDA0005031628150000022
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Patent Application Serial No. 63 / 297,339, filed on January 7, 2022. The disclosure of the prior application is considered part of (and incorporated by reference into) the disclosure of this application.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically as an XML file named "07039-2095WO1_SL.xml". This XML file was created on December 12, 2022 and is 10,000 bytes in size. The material in the XML file is incorporated herein by reference in its entirety. Technical Field
[0005] This article relates to methods and materials used in treating mammals (e.g., humans) with cancer and / or infectious diseases.For example, a recombinant human cytomegalovirus (hCMV) vector is provided herein, which includes (e.g., designed to include) nucleic acid encoding a viral gene transfer vector genome (e.g., a heterologous viral gene transfer vector genome) and one or more nucleic acids encoding a packaging polypeptide, so that the mammalian cells infected with the hCMV vector can produce and release a viral vector (e.g., an infectious lentiviral vector, which can then infect cells (e.g., immune cells) in vivo and / or can be recognized and internalized via antigen presenting cells (APC), and can optionally drive the expression of exogenous polypeptides (e.g., therapeutic polypeptides or antigen receptors such as chimeric antigen receptors (CAR)) in infected immune cells in mammals (e.g., humans), to induce an immune response in mammals. In some cases, a recombinant hCMV vector provided herein can be given to a mammal with cancer and / or an infectious disease, to induce an immune response (e.g., to treat the mammal) against cancer and / or a pathogen causing an infectious disease in mammals. Background Art
[0006] Viral vectors are reliable tools for transferring exogenous genetic material or genomic manipulation components into target cells (Warnock et al., Methods Mol. Biol., 737: 1-25 (2011)). For example, lentiviral vectors can integrate exogenous genes into the host genome, while adeno-associated virus (AAV) vectors can be produced in high titers and present feasible in vivo infection efficiency (Maes et al., Neurosci. Lett., 707: 134310 (2019)). Summary of the invention
[0007] The current scheme for producing genetically modified T cells (CAR T cells) expressing CAR includes isolating autologous T cells from the patient, activating and proliferating the isolated T cells with cytokines, transducing T cells in vitro with a lentivirus designed to express CAR, thereby forming CAR T cells, and infusing CAR T cells back into the patient (Tyagarajan et al., Mol. Ther. Methods Clin. Dev., 16: 136-144 (2019)). The present disclosure is based at least in part on the design of recombinant hCMV, which can be given to patients to achieve in vivo immune cell editing (e.g., CAR T cell generation) by a single step.
[0008] This article relates to methods and materials used in treating mammals (e.g., humans) with cancer and / or infectious diseases.For example, a recombinant hCMV vector is provided herein, which includes (e.g., designed to include) nucleic acid encoding a viral vector genome (e.g., a heterologous viral gene transfer vector genome) and one or more nucleic acids encoding a packaged polypeptide, and can infect mammalian cells. In some cases, cells infected by hCMV vectors can produce and release viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)), which can infect other cells (e.g., immune cells (such as T cells)) in vivo, and can optionally drive mammals (e.g., humans) in vivo through viral vector infected cells in exogenous polypeptides (e.g., therapeutic polypeptides or antigen receptors (such as CAR)) expression, to induce an immune response in mammals. In some cases, cells infected with hCMV vectors can produce and release viral vectors derived from viruses (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)), which can cause infectious diseases and can be recognized as pathogens by APCs in vivo, so that the viral vectors are internalized by APCs, and one or more polypeptides from the viral vectors are presented as antigens to one or more immune cells (e.g., T cells) to induce an immune response in a mammal. Also provided herein are methods and materials for preparing and using such recombinant hCMV vectors. In some cases, a mammal suffering from cancer can be given a recombinant hCMV vector provided herein to induce an immune response to the cancer in a mammal (e.g., to treat a mammal). In some cases, a mammal suffering from an infectious disease can be given a recombinant hCMV vector provided herein to induce an immune response to a pathogen causing an infectious disease in a mammal (e.g., to treat a mammal).
[0009] As described herein, a recombinant hCMV population designed to infect cells in a mammal is administered to produce cells infected with hCMV vectors in a mammal, thereby producing and releasing viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)) that can infect other cells (e.g., T cells) in vivo, which can result in in vivo editing of one or more immune cell functions of cells infected with viral vectors (e.g., T cells infected with lentiviral vectors). For example, the recombinant hCMV vectors provided herein can infect cells in a mammal (e.g., a human), and can produce one or more endogenous hCMV polypeptides to recruit one or more immune cells to infected cells (e.g., fibroblasts infected with hCMV vectors, endothelial cells infected with hCMV vectors, monocytes infected with hCMV vectors, or glial cells infected with hCMV vectors), so that the viral vectors produced and released by cells infected with hCMV vectors can infect the recruited immune cells. In some cases, the viral vector produced and released by the cells infected by the hCMV vector can include nucleic acids encoding exogenous polypeptides (e.g., therapeutic polypeptides and / or antigen receptors (such as CAR)), so that when the viral vector infects the recruited immune cells, the recruited immune cells infected by the viral vector can express exogenous polypeptides. For example, the recombinant hCMV vector provided herein can be designed to produce a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) containing nucleic acids encoding therapeutic polypeptides, so that the viral vector can infect recruited immune cells (e.g., T cells), and the infected recruited immune cells can express therapeutic polypeptides. For example, the recombinant hCMV vector provided herein can be designed to produce a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) containing nucleic acids encoding CAR, so that the viral vector can infect recruited immune cells (e.g., T cells), and the infected recruited immune cells can express CAR to generate CAR+ immune cells (e.g., CAR+T cells) in vivo. As demonstrated herein, the recombinant hCMV provided herein can also be further designed to have a changed tropism. For example, the recombinant hCMV can be designed to include a nucleic acid sequence encoding a functional UL131 polypeptide (e.g., a UL131 nucleic acid sequence from a hCMV Merlin strain), which can allow hCMV to infect non-fibroblasts (such as epithelial cells, endothelial cells, monocytes, and glial cells).
[0010] The ability to induce an immune response in a mammal as described herein, and optionally generate CAR T cells in a mammal, provides a unique opportunity to target (e.g., locate and destroy) specific cells (e.g., disease cells (such as cancer cells) and infected cells (such as virus-infected cells)) using immunotherapy.
[0011] Generally speaking, one aspect of this paper describes a recombinant hCMV vector capable of infecting mammalian cells. The hCMV vector comprises a heterologous nucleic acid, which encodes: (i) a heterologous viral gene transfer vector genome and (ii) one or more auxiliary polypeptides, which are used to amplify the heterologous viral gene transfer vector genome and package it into infectious vector particles, wherein the cells infected by the hCMV vector produce and release infectious vector particles comprising the gene transfer vector genome. The hCMV vector can be replicative in cells. The hCMV vector can lack nucleic acids encoding UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector can lack UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector can be derived from hCMV AD169 strain or hCMV Merlin strain. The hCMV vector lacks a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The hCMV vector lacks a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The cell can be a fibroblast, an epithelial cell, an endothelial cell, a monocyte or a glial cell. The viral gene transfer vector genome can be a lentiviral vector genome, a retroviral vector genome, an AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome. The viral gene transfer vector genome can include a nucleic acid sequence encoding a therapeutic polypeptide or an antigen receptor polypeptide, wherein the infectious vector particles comprising the gene transfer vector genome can infect immune cells in a mammal, and wherein the infected immune cells can guide the expression of the therapeutic polypeptide or the antigen receptor polypeptide. In some cases, the viral gene transfer vector genome may include a nucleic acid sequence encoding a therapeutic polypeptide. The therapeutic polypeptide can be a chemokine, a cytokine, an anti-PD1 antibody, an anti-PDL-1 antibody, an anti-CTLA-4 antibody or a CD47 polypeptide.In some cases, the viral gene transfer vector genome may include a nucleic acid sequence encoding an antigen receptor polypeptide.Antigen receptor polypeptides may be CAR polypeptides (e.g., anti-CD19 CAR).Immune cells may be T cells, natural killer (NK) cells, or natural killer T (NKT) cells.In infected immune cells, the viral gene transfer vector may be a replication-deficient type.The viral gene transfer vector genome may include one or more packaging elements selected from the following groups: 5' long terminal repeats (LTR), 3'LTR, Ψ (psi) elements, Rev response elements (RRE), and central polypurine region / central termination sequence (cPPT / CTS).The nucleic acid encoding one or more auxiliary polypeptides may include nucleic acids encoding envelope polypeptides selected from the following groups: vesicular stomatitis virus G (VSV G) polypeptides and murine leukemia virus (MLV) 4070A polypeptides.The released viral gene transfer vector may include envelope polypeptides.
[0012] In another aspect, the invention features a method for treating a mammal suffering from cancer. The method may include administering a recombinant hCMV vector to a mammal suffering from cancer or the method is essentially composed of it, wherein the hCMV vector is capable of infecting cells of the mammal, wherein the hCMV comprises a heterologous nucleic acid encoding: (i) a heterologous viral gene transfer vector genome comprising a nucleic acid sequence encoding an antigen receptor polypeptide of a cancer antigen targeting the cancer; (ii) one or more auxiliary polypeptides for amplifying the heterologous viral gene transfer vector genome and packaging it into infectious vector particles, wherein the cells infected by the hCMV vector produce and release infectious vector particles comprising the gene transfer vector genome, and wherein the released infectious vector particles are capable of infecting immune cells in the mammal and directing the infected immune cells to express the antigen receptor polypeptide, and wherein the infected immune cells expressing the antigen receptor reduce the number of cancer cells in the mammal. The mammal may be a human. The cancer may be brain cancer, B cell lymphoma, ALL, CLL, neuroblastoma, breast cancer, or lung cancer. Cancer antigens can be cluster of differentiation 19 (CD19), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, mucin 1 (MUC-1), epithelial tumor antigen (ETA), melanoma-associated antigen (MAGE), human epidermal growth factor receptor 2 (HER2), biotin, EGFRvIII, CD171 or mesothelin. The hCMV vector can be replicative in cells. The hCMV vector can lack nucleic acids encoding UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector can lack UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector can be derived from hCMV AD169 strain or hCMV Merlin strain.The hCMV vector may lack a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The hCMV vector may lack a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The cell can be a fibroblast, an epithelial cell, an endothelial cell, a monocyte or a glial cell. The viral gene transfer vector genome can be a lentiviral vector genome, a retroviral vector genome AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome. The viral gene transfer vector can include a nucleic acid encoding one or more packaging elements selected from the group consisting of: 5'LTR, 3'LTR, Ψ(psi) element, RRE and cPPT / CTS. The nucleic acid encoding one or more auxiliary polypeptides can include a nucleic acid encoding an envelope polypeptide selected from the group consisting of: VSV G protein or MLV 4070A protein. The released viral gene transfer vector can include an envelope polypeptide.
[0013] In another aspect, the present invention is characterized in that it is used to treat a method for treating a mammal suffering from an infectious disease. The method may include administering a recombinant hCMV vector to the mammal suffering from an infectious disease or the method is essentially composed of it, wherein the hCMV vector is capable of infecting the cells of the mammal, wherein the hCMV comprises a heterologous nucleic acid encoding: (i) a heterologous viral gene transfer vector genome, which is derived from a virus causing an infectious disease; and (ii) one or more auxiliary polypeptides, which are used to amplify the heterologous viral gene transfer vector genome and package it into infectious vector particles, wherein the cells infected by the hCMV vector produce and release infectious vector particles containing the gene transfer vector genome, and wherein the infectious vector particles are recognized by the APC in the mammal, so that the APC presents the antigen from the viral gene transfer vector to the T cells in the mammal, and wherein the T cells recognize and destroy the virus causing the infectious disease in the mammal. The mammal can be a human. The infectious disease can be viral pneumonia, acquired immunodeficiency syndrome or viral hepatitis. The hCMV vector can be replicative in the cell. The hCMV vector may lack nucleic acid encoding UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector may lack UL138 polypeptide, UL144 polypeptide, UL146 polypeptide, UL147 polypeptide or miR-UL148D. The hCMV vector may be derived from hCMV AD169 strain or hCMV Merlin strain. The hCMV vector may lack a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The hCMV vector may lack a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide. The cell can be a fibroblast, an epithelial cell, an endothelial cell, a monocyte or a glial cell. The viral gene transfer vector genome can be a lentiviral vector genome, a retroviral vector genome, an AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome.The viral gene transfer vector genome may comprise a nucleic acid encoding one or more packaging elements selected from the group consisting of: 5'LTR, 3'LTR, Ψ(psi) element, RRE and cPPT / CTS. The nucleic acid encoding one or more auxiliary polypeptides may comprise a nucleic acid encoding an envelope polypeptide selected from the group consisting of: VSV G protein or MLV 4070A protein. The released viral gene transfer vector may comprise an envelope polypeptide.
[0014] Unless otherwise defined, the meaning of all technical and scientific terms used in the present invention is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar to or equivalent to those described in the present invention can be used in the practice of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references described in the present invention are incorporated herein by reference in their entirety. In the event of a conflict, the present application specification including definitions shall prevail. In addition, materials, methods and embodiments are illustrative only and are not intended to be limiting.
[0015] The drawings and the following description further illustrate one or more embodiments of the present invention in detail. Other features, objectives and advantages of the present invention can be clearly seen from the description, drawings and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 . Construction of exemplary hCMV-BAC. The BAC vector containing the left homology arm (hCMV unique short (US) US27-28 sequence) and the right homology arm (hCMV US29-30 sequence) is linearized and co-transfected with the AD169 or Merlin linear genome into MRC-5 cells to generate recombinant hCMV-BAC virus. The green plaques of the recombinant virus are purified, and then the circular viral DNA is isolated from the cells infected by the hCMV-BAC. The circular viral BAC DNA is transformed into Escherichia coli DH10B cells and colonies containing the full-length hCMV genome are selected. The BAC plasmid carrying the hCMV genome is then extracted and transferred to the Escherichia coli SW102 cells containing the λ red recombineering system. The hCMV-BAC plasmid can be genetically manipulated in SW102 cells, and the BAC sequence can be removed by transfecting the plasmid containing the BAC into cells that stably express the Cre recombinase.
[0017] Figure 2A-2B . Construction of an exemplary tropism-repairing hCMV. Figure 2A : The unique long (UL) UL131a-like sequence in the hCMV AD169 strain has been replaced by the functional UL131 in the Merlin strain. Figure 2B : The repair tropism was confirmed in U251 human glioma cells.
[0018] Figure 3A-3B . Construction of an exemplary hCMV vector capable of encoding and driving lentiviral synthesis. Figure 3A :Two hCMV vectors have been constructed. Each vector expresses a lentiviral vector genome derived from HIV, and also contains nucleic acids that can express structural polypeptides for packaging the lentiviral vector genome derived from HIV (e.g., gag nucleic acids encoding Gag protein, pol nucleic acids encoding DNA polymerase, rev nucleic acids encoding transactivating proteins, and nucleic acids encoding glycoproteins or envelope (Env) proteins). One hCMV vector expresses VSV-G glycoprotein (AD169-BAC R5.3) for packaging a lentiviral vector genome derived from HIV, and another hCMV expresses a dual-tropic murine leukemia virus (MLV) 4070AEnv protein (AD169-BAC R5.4) for packaging a lentiviral vector genome derived from HIV. The lentiviral vector genome derived from HIV includes HIV-LTR, HIV-1Ψ, RRE, cPPT / CTS, a transgene driven by a promoter sequence (dTomato is used herein as a reporter gene) and an enhancer sequence. Figure 3B : Reporter gene expression of AD169-BAC R5.4 was confirmed in MRC-5 human fibroblasts 9 days post-transfection (dpt).
[0019] Figure 4 hCMV vectors can encode and drive the synthesis of infectious lentivirus. hCMV vectors (AD169-BACR5.3 or AD169-BAC R5.4) were transfected into 293T cells and the supernatant was collected and renewed every day. Then the collected supernatant was added to fresh 293T cells. dTomato transduced by lentivirus was observed and counted 4 days after infection. + GFP-293T red plaques.
[0020] Figure 5 .Optimization of hCMV R5.4 lentiviral synthesis efficiency. Mutant hCMV R5.4 vectors were constructed by deleting US1-US11, US14-US22 or UL23 and named R5.4.1, R5.4.2 and R5.4.4 respectively. R5.4.1, R5.4.2 and R5.4.4 vectors were transfected into 293T cells. Supernatants were collected on days 5 and 8 after transfection. The collected supernatants were then added to fresh 293T cells. dTomato transduced by lentivirus was observed and counted 4 days after infection. + GFP-293T red plaques.
[0021] Figure 6.Optimization of hCMV R5.3 and R5.4 lentiviral synthesis efficiency. Mutant hCMV was constructed by deleting US14-US22, US30, UL23, UL83 (pp65) or UL83 (pp71), and named R5.4.2 / R5.3.2, R5.4.3 / R5.3.3, R5.4.4 / R5.3.4, R5.4.5 / R5.3.5, R5.4.6 / R5.3.6, respectively. The mutant vector was transfected into 293T cells. The supernatant was collected on the 3rd and 6th day after transfection. The collected supernatant was then added to fresh 293T cells. Observe and count the dTomato transduced by the lentivirus 4 days after infection + GFP-293T red plaques.
[0022] Figure 7 . Construction of an exemplary hCMV vector that can encode and drive lentivirus synthesis in a controllable manner. The vector expresses a lentiviral vector genome derived from HIV, and also contains nucleic acids that can express structural polypeptides for packaging the lentiviral vector genome derived from HIV (e.g., gag nucleic acids encoding Gag proteins, pol nucleic acids encoding DNA polymerases, rev nucleic acids encoding transactivators, and nucleic acids encoding Env proteins). The expression of transactivators and VSV-G Env proteins is driven by drug-controllable promoters (such as tetracycline (tet) inducible shut-off systems (pRSV-tTA-pTight)). The lentiviral vector genome derived from HIV contains HIV-LTR, HIV-1Ψ, RRE, cPPT / CTS, and a transgene (CD19CAR) driven by a lymphocyte-specific CD43 promoter sequence. dTomato is used as a reporter gene. DETAILED DESCRIPTION
[0023] This article relates to methods and materials related in treating mammals (e.g., people) with cancer and / or infectious diseases.For example, a recombinant hCMV vector is provided herein, which is a replicating type in infected cells, and is designed to infect cells in mammals to produce cells infected by hCMV vectors in mammals, and the cells then produce and release viral vectors (e.g., heterologous viral gene transfer vectors, such as other cells (e.g., T cells) can be infected in vivo and / or can be recognized and internalized by APCs. Slow virus vectors), and exogenous polypeptides (e.g., therapeutic polypeptides or antigen receptors (such as CAR)) can be optionally driven to be expressed in infected cells in mammals (e.g., people) to induce an immune response in mammals. In some cases, the viral vectors produced and released by cells infected by hCMV vectors provided herein can include nucleic acids encoding exogenous polypeptides (e.g., therapeutic polypeptides or antigen receptors (such as CAR)), so that when viral vectors infect cells (e.g., immune cells, such as T cells recruited by cells infected by hCMV vectors), viral vector-infected cells can express exogenous polypeptides. For example, the recombinant hCMV vector provided herein can be designed so that the viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) produced and released by the hCMV vector-infected cell can include a nucleic acid encoding a therapeutic polypeptide, so that the viral vector can infect cells (e.g., immune cells (such as T cells) recruited by cells infected by the hCMV vector) and the cells infected by the viral vector can express the therapeutic polypeptide. For example, the recombinant hCMV vector provided herein can be designed so that the viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) produced and released by the hCMV vector-infected cell can include a nucleic acid encoding a CAR, so that the viral vector can infect cells (e.g., immune cells (such as T cells) recruited by cells infected by the hCMV vector) and the cells infected by the viral vector can express CAR, thereby generating CAR in vivo + Immune cells (such as CAR + T cells). In some cases, the viral vector produced and released by the cells infected by the hCMV vectors provided herein can be derived from pathogenic viruses, so that the viral vector is internalized by APC. For example, the recombinant hCMV vectors provided herein can be designed so that the viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)) produced and released by the cells infected by the hCMV vectors can be recognized as pathogens by APCs, so that the viral vectors are internalized by APCs, and one or more polypeptides from the viral vectors are presented as antigens to immune cells (e.g., T cells).
[0024] The recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce cells infected by the hCMV vector in a mammal, which in turn produce and release viral vectors, such as slow virus vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APC) can infect any type of cell. In some cases, the recombinant hCMV vector provided herein can infect fibroblasts, endothelial cells, monocytes and / or glial cells.
[0025] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be replication-competent (e.g., can be replication-competent within hCMV vector-infected cells).
[0026] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be non-pathogenic (e.g., to a mammal being treated as described herein).
[0027] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can infect dividing cells (e.g., can only infect dividing cells).
[0028] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can infect non-dividing cells (e.g., can only infect non-dividing cells).
[0029] The recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in mammals to produce hCMV vector-infected cells in mammals, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be derived from (e.g., can include genomic elements, such as nucleic acids encoding polypeptides (or fragments thereof)) any suitable hCMV. Examples of hCMV include, but are not limited to, hCMV AD169 strains, hCMV Merlin strains, hCMV Towne strains, hCMV TB40 strains, and hCMVToledo strains.
[0030] The recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector, which is designed to infect cells in a mammal, to produce cells infected by the hCMV vector in a mammal, which in turn produce and release a viral vector, such as a slow virus vector that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APC) can include one or more heterologous nucleotide sequences. As used herein, a heterologous nucleotide sequence can be any nucleotide sequence that is not naturally produced in hCMV (e.g., non-naturally produced in hCMV before recombination). The nucleotide sequence that is not naturally produced in hCMV can be from any suitable source. In some cases, the nucleotide sequence that is not naturally produced in hCMV can be from a non-viral organism. In some cases, the nucleotide sequence that is not naturally produced in hCMV can be from a virus other than hCMV (e.g., slow virus, such as human immunodeficiency virus (HIV), adeno-associated virus (AAV), retrovirus, vesicular stomatitis virus (VSV) or murine leukemia virus (MLV) (such as double-tropic MLV)). In some cases, the non-natural nucleotide sequence produced in hCMV can be from CMV obtained from different species. In some cases, the non-natural nucleotide sequence produced in hCMV can be from different hCMV strains (for example, strains with different serotypes). In some cases, the non-natural nucleotide sequence produced in hCMV can be a synthetic nucleotide sequence.
[0031] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in mammals to produce hCMV vector-infected cells in mammals, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can include one or more nucleic acids that allow cells infected by hCMV vectors to produce and release viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)). For example, the recombinant hCMV vectors provided herein can include nucleic acids that can encode one or more polypeptides, which are used to amplify and / or package viral vector genomes (e.g., heterologous viral gene transfer vector genomes) into infectious vector particles containing viral vector genomes. In some cases, the recombinant hCMV vector can include a viral vector genome containing a viral vector packaging element (e.g., a viral vector genome derived from a virus other than hCMV), and can include one or more nucleic acids encoding a viral vector packaging polypeptide (e.g., a polypeptide capable of packaging a viral vector genome to produce a viral vector).
[0032] The viral vector genome that can be encoded by the recombinant hCMV vector provided herein can be any suitable viral vector genome. In some cases, the viral vector genome is not a herpes virus vector genome. In some cases, the viral vector genome is a viral gene transfer vector genome. The example of the viral vector genome that can be encoded by the recombinant hCMV vector provided herein includes but is not limited to a lentiviral vector genome, a retroviral vector genome, an AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, and a coronavirus vector genome. The viral vector packaging element that can be included in the viral vector genome encoded by the recombinant hCMV vector provided herein includes but is not limited to a long terminal repeat sequence (LTR), which includes 5'LTR and 3'LTR (each of which can include U3 district, R district and U5 district), Ψ (psi) element, Rev response element (RRE) and central polypurine region / central termination sequence (cPPT / CTS). The nucleic acid encoding the viral vector packaging polypeptide (for example, capable of packaging the viral vector genome to produce a polypeptide of a viral vector) that can be included in the recombinant hCMV vector provided herein can encode any suitable viral vector packaging polypeptide. Examples of nucleic acids encoding viral vector packaging polypeptides include, but are not limited to, gag nucleic acids (e.g., nucleic acids encoding group-specific antigen (Gag) proteins), pol nucleic acids (e.g., nucleic acids encoding DNA polymerases), rev nucleic acids (e.g., nucleic acids encoding transactivator proteins), and env nucleic acids (e.g., nucleic acids encoding envelope proteins with or without glycoproteins).
[0033] In some cases, the recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector, which is designed to infect cells in a mammal, to produce cells infected by hCMV vectors in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APC) encoded viral vector genomes (e.g., viral gene transfer vector genomes (such as lentiviral vectors)) can also include transgenes (e.g., nucleic acids encoding therapeutic polypeptides or antigen receptors (such as CAR)). In the case where the recombinant hCMV vector provided herein includes a transgene, the transgene can be any suitable transgene. In some cases, the transgene can be a nucleotide sequence encoding a detectable marker. Examples of detectable markers include, but are not limited to, fluorophores (e.g., green fluorescent protein (GFP), mCherry, yellow fluorescent protein (YFP), cyan fluorescent protein (CFP) and dTomato), enzymes (e.g., luciferase, CRISPR-associated protein 9 (Cas9), Cre recombinase, restriction enzymes, invertases, thymidine kinases, and sodium / iodine symporters (symporter) (NIS)).
[0034] In some cases, a transgene that may be included in a viral vector genome (e.g., a viral gene transfer vector genome (such as a lentiviral vector)) encoded by a recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce hCMV vector-infected cells in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APCs) may include a nucleotide sequence encoding a receptor (e.g., CAR). Receptors (such as CAR) can target any appropriate antigen (e.g., cancer antigens). Examples of antigens that can be targeted by the transgene-encoded receptors in the recombinant hCMV vectors provided herein include, but are not limited to, cluster of differentiation 19 (CD19; associated with B-cell lymphoma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL)), B-cell maturation antigen (BCMA: associated with multiple myeloma (MM)), alpha-fetoprotein (AFP; associated with germ cell tumors and / or hepatocellular carcinoma), carcinoembryonic antigen (CEA; associated with intestinal cancer, lung cancer, and / or breast cancer), CA-125 (associated with ovarian cancer), mucin 1 (MUC-1; associated with breast cancer), epithelial tumor antigen (ETA; associated with breast cancer), melanoma-associated antigen (MAGE; associated with malignant melanoma), human epidermal growth factor receptor 2 (HER2; associated with breast cancer), biotin (associated with EGFRvIII-positive cancers)), EGFRvIII (associated with gliomas), CD171 (associated with neuroblastoma), and mesothelin (associated with mesothelioma, pancreatic cancer, and non-small cell lung cancer).
[0035] In some cases, a transgene that may be included in a viral vector genome (e.g., a viral gene transfer vector genome (such as a lentiviral vector)) encoded by a recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce hCMV vector-infected cells in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APCs) may include a nucleotide sequence encoding a therapeutic polypeptide. Examples of therapeutic polypeptides include, but are not limited to, immunomodulatory factors (such as chemokines and cytokines), antibodies (such as antibodies that block immune checkpoint molecules (e.g., PD-1, PDL-1, and CTLA-4)), and CD47 polypeptides.
[0036] When a transgene in a viral vector genome (e.g., a viral gene transfer vector genome (such as a lentiviral vector)) encoded by a recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce cells infected by an hCMV vector in a mammal, which in turn produces and releases a viral vector, such as a lentiviral vector that can infect other cells (such as T cells) and / or can be recognized and internalized by an APC) includes a nucleotide sequence encoding a CAR, the CAR can be any suitable CAR. CAR may include an antigen binding domain, an optional hinge, a transmembrane domain, and one or more signaling domains. The antigen binding domain of a CAR expressed by a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) can be any suitable antigen binding domain, the viral vector is produced and released by a cell infected by a recombinant hCMV vector provided herein, and the recombinant hCMV vector can be administered to a mammal (e.g., a human) as described herein. In some cases, an antigen binding domain may include an antibody or fragment thereof targeting an antigen (e.g., a cancer antigen (such as a CD19 polypeptide)). Examples of antigen binding domains include, but are not limited to, antigen binding fragments (Fab), variable regions of antibody heavy chains (VH), variable regions of light chains (VL), single-chain variable fragments (scFv), and domains of growth factors bound to cancer cell-specific receptors (e.g., domains from EGF, PDGR, FGF, TGF, or derivatives thereof). In some cases, antigen binding domains can target (e.g., can be targeted and bound to) tumor-specific antigens. For example, the recombinant hCMV vector provided herein can be designed to produce a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) that can express CAR, and the CAR can be bound to a tumor-specific antigen (e.g., an antigen present on a cancer cell is expressed in small amounts or not expressed on a non-cancerous cell type).In some cases, the antigen binding domain of the CAR can be as described elsewhere herein (see, e.g., U.S. Patent Application Publication No. 2017 / 0183418, such as paragraph
[0015] and the sequence listing of U.S. Patent Application Publication No. 2017 / 0183413, such as paragraph
[0049] , FIG. 2, Table 9 and the sequence listing of U.S. Patent Application Publication No. 2017 / 0183413; U.S. Patent Application Publication No. 2018 / 0291079, such as ... Paragraphs
[0041] -
[0045] and Table 4 of U.S. Patent Application Publication No. 2018 / 0291079; U.S. Patent Application Publication No. 2020 / 0289563, such as paragraphs
[0006] -
[0053] ,
[0186] -
[0189] and Table 1 of U.S. Patent Application Publication No. 2020 / 0289563; and U.S. Patent Application Publication No. 2003 / 0211097, such as paragraphs
[0081] and [0211-0215] and the sequence listing of U.S. Patent Application Publication No. 2003 / 0211097.
[0037] In some cases, the CAR expressed by the viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) produced and released by the cells infected by the recombinant hCMV vector provided herein may include an optional hinge region. In some cases, the hinge region may be located between the antigen binding domain and the transmembrane domain of CAR. In some cases, the hinge region can increase the flexibility of the CAR antigen binding domain. For example, the hinge region can reduce the spatial restriction between the antigen binding domain of CAR and its target antigen (e.g., increase the binding between the antigen binding domain of CAR and its target antigen). Examples of hinge regions that can be used as described herein include, but are not limited to, membrane-proximal regions from IgG, membrane-proximal regions from CD8, and membrane-proximal regions from CD28. In some cases, the hinge region of the CAR can be as described elsewhere herein (see, e.g., U.S. Patent Application Publication No. 2018 / 0000914, such as paragraph
[0168] and Table 1 of U.S. Patent Application Publication No. 2018 / 0000914; U.S. Patent Application Publication No. 2017 / 0183418, such as paragraphs
[0034] ,
[0037] ,
[0040] and Table 2 of U.S. Patent Application Publication No. 2017 / 0183413, such as paragraph
[0116] of U.S. Patent Application Publication No. 2017 / 0183413; and U.S. Patent Application Publication No. 2017 / 0145094, such as paragraph
[0104] of U.S. Patent Application Publication No. 2017 / 0145094).
[0038] The transmembrane domain of a CAR that can be expressed by a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) can include any suitable transmembrane domain, and the viral vector is produced and released by cells infected with a recombinant hCMV vector provided herein, and the recombinant hCMV vector can be given to a mammal (e.g., a person) as described herein. The transmembrane domain can be located between the antigen binding domain and the signaling domain of CAR and / or between the hinge and the signaling domain of CAR. In some cases, the transmembrane domain can provide structural stability for CAR. For example, the transmembrane domain can include a structure (e.g., a hydrophobic alpha helical structure) that can span the cell membrane and can anchor CAR to the plasma membrane. Examples of transmembrane domains that can be used as described herein include, but are not limited to, CD3ζ transmembrane domains, CD4 transmembrane domains, CD8 (e.g., CD8α) transmembrane domains, CD28 transmembrane domains, CD16 transmembrane domains, and erythropoietin receptor transmembrane domains. In some cases, the transmembrane domain of the CAR can be as described elsewhere herein (see, e.g., U.S. Patent Application Publication No. 2016 / 0120906, such as paragraphs
[0155] ,
[0161] ,
[0269] , Figure 4 and FIG. 11 ; U.S. Patent Application Publication No. 2019 / 0209616, such as paragraph
[0026] of U.S. Patent Application Publication No. 2019 / 0209616; U.S. Patent Application Publication No. 2018 / 0000914, such as paragraphs
[0168] -
[0171] of U.S. Patent Application Publication No. 2018 / 0000914; U.S. Patent Application Publication No. 2017 / 0183418, such as U.S. Patent Application Publication No. 2017 / 0183418, paragraphs
[0116] -
[0118] ; U.S. Patent Application Publication No. 2017 / 0183413, such as paragraphs
[0116] -
[0118] of U.S. Patent Application Publication No. 2017 / 0183413; and U.S. Patent Application Publication No. 2017 / 0145094, such as paragraphs
[0104] -
[0107] of U.S. Patent Application Publication No. 2017 / 0145094.
[0039] One or more signaling domains of a CAR that can be expressed by a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) can include any suitable signaling domain or combination of signaling domains (e.g., a combination of two, three or four signaling domains), the viral vector being produced and released by cells infected with a recombinant hCMV vector provided herein, the recombinant hCMV vector being administered to a mammal (e.g., a human) as described herein. In some cases, the signaling domain of a CAR can be an intracellular signaling domain that is normally present in a T cell or NK cell. Examples of signaling domains that can be used as described herein include, but are not limited to, CD2 signaling domains, CD3 ζ signaling domains, CD28 signaling domains, Toll-like receptor (TLR) signaling domains (e.g., TLR3 or TLR4 signaling domains), CD27 intracellular signaling domains, OX40 (CD134) intracellular signaling domains, 4-1BB (CD137) intracellular signaling domains, CD278 intracellular signaling domains, DAP10 intracellular signaling domains, DAP12 intracellular signaling domains, FceRly intracellular signaling domains, CD278 intracellular signaling domains, CD122 intracellular signaling domains, CD132 intracellular signaling domains, CD70 intracellular signaling domains, cytokine receptor intracellular signaling domains, and CD40 intracellular signaling domains. In some cases, the CAR used as described herein can be designed as a first generation CAR with a CD3 ζ intracellular signaling domain. In some cases, the CAR used as described herein can be designed as a second generation CAR with a CD28 intracellular signaling domain, followed by a CD3 ζ intracellular signaling domain. In some cases, the CAR used as described herein can be designed as a third generation CAR, which has (a) a CD28 intracellular signaling domain, followed by (b) a CD27 intracellular signaling domain, an OX40 intracellular signaling domain, or a 4-1BB intracellular signaling domain, followed by (c) a CD3 ζ intracellular signaling domain. In some cases, the intracellular signaling domain of the CAR can be as described elsewhere herein (see, e.g., U.S. Patent Application Publication No. 2018 / 0000914, such as paragraphs
[0164] -
[0167] of U.S. Patent Application Publication No. 2018 / 0000914; and U.S. Patent Application Publication No. 2017 / 0183413, such as paragraphs
[0112] -
[0115] of U.S. Patent Application Publication No. 2017 / 0183413).
[0040] Examples of CARs expressed by viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)) that can be produced and released by cells infected with the recombinant hCMV vectors described herein include, but are not limited to, EGFRvIII CAR, GD2 CAR, IL-13RA CAR, CD19 CAR, BCMACAR, CD138 CAR, NKG2-D CAR, HER2 CAR, CD137 CAR, and B7-H3 CAR.
[0041] In addition to the transgene, the viral vector genome encoded by the recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce cells infected by the hCMV vector in a mammal, which in turn produces and releases a viral vector, such as a lentiviral vector that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APC) also contains one or more regulatory elements operably connected to the transgene (e.g., a nucleic acid encoding a therapeutic polypeptide or an antigen receptor (such as a CAR)). Such regulatory elements may include inducible elements, promoter sequences, enhancer sequences, response elements, signal peptides, internal ribosome entry sequences, polyadenylation signals, or terminators that regulate nucleic acid expression (e.g., transcription or translation). The selection of regulatory elements that may be included in the viral vector genome depends on several factors, including but not limited to inducibility, targeting, and desired expression levels. For example, a promoter may be included in the viral vector genome to promote transcription of the transgene. The promoter may be a naturally occurring promoter or a recombinant promoter. The promoter can be ubiquitous or inducible (e.g., in the presence of tetracycline), and can affect the expression of the nucleic acid encoding the polypeptide in a general or tissue-specific manner (e.g., T cell-specific promoters, NK cell-specific promoters, B cell-specific promoters, and NKT cell-specific promoters). Examples of promoters that can be used to drive the expression of the imported protein polypeptide in the cell include, but are not limited to, cytomegalovirus / chicken β-actin (CBA) promoter, cytomegalovirus (CMV) promoter, ubiquitin C (UbC) promoter, EF1a promoter, Rous sarcoma virus long terminal repeat (RSV) promoter, human T-lymphotropic virus type I (HTLV-I) promoter, CD43 promoter, B29 promoter, CD14 promoter, and CD3D promoter. As used herein, "operably connected" refers to the position of the regulatory element in the viral vector genome relative to the transgenic to allow or promote the expression of the encoded polypeptide. For example, the viral vector genome can contain a promoter and a transgenic. In this case, the promoter is operably connected to the transgenic so that it drives the expression of the transgenic in the cell.
[0042] In some cases, the viral vector genome that can be encoded by the recombinant hCMV vector provided herein can comprise the nucleic acid sequence shown as SEQ ID NO: 1 (see, e.g., Example 2).
[0043] In some cases, the viral vector genome that can be encoded by the recombinant hCMV vectors provided herein can be as described elsewhere (see, e.g., U.S. Patent Application Publication No. 2004 / 014702A1, e.g., FIG. 2 ).
[0044] In some cases, the genome of the recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce cells infected by the hCMV vector in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APC) can include a functional UL132 sequence. For example, the genome of the recombinant hCMV vector provided herein can include a UL132 sequence that can encode a functional UL132 polypeptide that makes the recombinant hCMV vector replicable in the infected cells of a mammal.
[0045] In some cases, the genome of the recombinant hCMV vector provided herein (e.g., a recombinant hCMV vector designed to infect cells in a mammal to produce cells infected by the hCMV vector in a mammal, which in turn produce and release a viral vector, such as a lentiviral vector that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by an APC) may include one or more modifications of one or more nucleic acids encoding a polypeptide of the hCMV genome and / or one or more viral elements. One or more modifications may be any appropriate modification. In some cases, one or more modifications in the hCMV genome may change the tropism of the recombinant hCMV vector. In some cases, one or more modifications in the hCMV genome may promote viral latency. In some cases, one or more modifications in the hCMV genome may recruit bone marrow cells. In some cases, one or more modifications in the hCMV genome may minimize or inhibit an immune response to the recombinant hCMV vector. Examples of modifications that may be made to nucleic acids encoding polypeptides or viral elements include, but are not limited to, deletions, insertions, and substitutions. For example, the recombinant hCMV vector provided herein may include one or more deletions in the hCMV genome. In some cases, the recombinant hCMV vectors provided herein can have at least one (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more) deletion of UL23, US1-US11, US30, US14-22, US30, UL83, UL82, UL138, UL144, UL146, UL147, and miR-UL148D. For example, the recombinant hCMV vector provided herein may have at least one of the following deletions: UL23, US1-US11, US30, US14-22, US30, UL83, UL82, UL138, UL144, UL146, UL147 and miR-UL148D, such that the recombinant hCMV vector lacks nucleic acid encoding a UL23 polypeptide, nucleic acid encoding a US1-US11 polypeptide, nucleic acid encoding a US30 polypeptide, nucleic acid encoding a US14-22 polypeptide, nucleic acid encoding a US30 polypeptide, nucleic acid encoding a UL83 polypeptide, nucleic acid encoding a UL82 polypeptide, nucleic acid encoding a UL138 polypeptide, nucleic acid encoding a UL144 polypeptide, nucleic acid encoding a UL146 polypeptide and / or nucleic acid encoding a UL147 polypeptide.For example, the recombinant hCMV vector provided herein can have following at least one (for example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or more) disappearance (for example, complete disappearance or partial disappearance): UL23, US1-US11, US30, US14-22, US30, UL83, UL82, UL138, UL144, UL146 and UL147, so that the recombinant hCMV vector lacks UL23 polypeptide, US1-US11 polypeptide, US30 polypeptide, US14-22 polypeptide, US30 polypeptide, UL83 polypeptide, UL82 polypeptide, UL138 polypeptide, UL144 polypeptide, UL146 and / or UL147 polypeptide. In some cases, the recombinant hCMV vector provided herein may include one or more replacements within the hCMV genome. For example, the recombinant hCMV vectors provided herein may have a UL131 sequence replaced with a heterologous UL131 sequence (e.g., replacing the defective AD169 UL131a sequence with a functional UL131 sequence from a hCMV Merlin strain) or may have a repaired UL131 sequence (e.g., a single A nucleotide deletion at position 77 of the defective AD169 UL131a sequence). For example, the recombinant hCMV vectors provided herein may have a UL131 sequence having a nucleotide sequence shown in SEQ ID NO: 2 (see, e.g., Example 3).
[0046] In the case where the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in a mammal to produce hCMV vector-infected cells in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) comprise one or more modifications to the hCMV genome, the one or more modifications can effectively increase the production of viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)) from the recombinant hCMV vector (e.g., compared to recombinant hCMV vectors lacking mutations). For example, a recombinant hCMV vector with UL23, US1-US11, US30, US14-22, US30, UL83 and / or UL82 deletions can increase the yield of viral vectors from the recombinant hCMV vector. In some cases, a recombinant hCMV vector with UL23, US1-US11, US30, US14-22, US30, UL83 and / or UL82 deletions can produce about 10 3 Transduction units (TU) / mL supernatant to about 10 6 TU / mL transduction units (TU) / mL supernatant (e.g., about 10 3 TU / mL to about 105 TU / mL, about 10 3 TU / mL to about 10 4 TU / mL, about 10 4 TU / mL to about 10 6 TU / mL, about 10 5 TU / mL to about 10 6 TU / mL, or about 10 4 TU / mL to about 10 5 TU / mL supernatant). For example, a recombinant hCMV vector with deletions of UL23, US1-US11, US30, US14-22, US30, UL83, and / or UL82 can produce about 10 4 TU / mL supernatant.
[0047] In the case where the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in mammals to produce hCMV vector-infected cells in mammals, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) comprise one or more modifications to the hCMV genome, the one or more modifications can effectively change the tropism of the recombinant hCMV vector (e.g., compared to a recombinant hCMV vector lacking a mutation). For example, a recombinant hCMV vector having a UL131 sequence from a hCMV Merlin strain, a hCMVTowne strain, a hCMV TB40 strain, or a hCMV Toledo strain can infect cell types that a recombinant hCMV vector lacking a mutation cannot infect. In some cases, a recombinant hCMV vector having a UL131 sequence from hCMV Merlin, hCMV Towne, hCMV TB40, or hCMV Toledo can infect epithelial cells, endothelial cells, monocytes, and glial cells in addition to fibroblasts.
[0048] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can contain (e.g., can be designed to contain) lentiviral (e.g., HIV) gag nucleic acid, lentiviral (e.g., HIV) pol nucleic acid, lentiviral (e.g., HIV) rev nucleic acid and VSV-G env nucleic acid, as well as a nucleic acid encoding a lentiviral genome comprising a lentiviral (e.g., HIV) LTR, a lentiviral (e.g., HIV) Ψ (psi) element, a lentiviral (e.g., HIV) RRE and a lentiviral (e.g., HIV) cPPT / CTS.
[0049] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in a mammal to produce hCMV vector-infected cells in the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can contain (e.g., can be designed to contain) lentiviral (e.g., HIV) gag nucleic acid, lentiviral (e.g., HIV) pol nucleic acid, lentiviral (e.g., HIV) rev nucleic acid and MLV env nucleic acid, and nucleic acid encoding a lentiviral genome comprising a lentiviral (e.g., HIV) LTR, a lentiviral (e.g., HIV) Ψ (psi) element, a lentiviral (e.g., HIV) RRE and a lentiviral (e.g., HIV) cPPT / CTS
[0050] In some cases, the recombinant hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells in a mammal to produce hCMV vector-infected cells in the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be used as Figure 3A shown.
[0051] hCMV vectors provided herein (e.g., recombinant hCMV vectors, designed to infect cells in mammals, to produce cells infected with hCMV vectors in mammals, which in turn produce and release viral vectors, such as slow virus vectors that can infect other cells (such as T cells) and / or can be recognized and internalized by APCs) infected cells produce and release viral vectors that can infect any type of cell. In some cases, the viral vectors produced and released by cells infected with hCMV vectors provided herein can infect immune cells. Examples of immune cells infected with viral vectors that can be produced and released by cells infected with hCMV vectors provided herein include, but are not limited to, T cells, NK cells, and NKT cells.
[0052] In some cases, the viral vectors produced and released by cells infected with the hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be replication-defective (e.g., can be replication-defective within viral vector-infected cells (such as viral vector-infected immune cells)).
[0053] In some cases, the viral vectors produced and released by cells infected with the hCMV vectors provided herein (e.g., recombinant hCMV vectors designed to infect cells within a mammal to produce hCMV vector-infected cells within the mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs) can be integrated into the genome of the infected cells (e.g., can be integrated into the genome of viral vector-infected cells (such as viral vector-infected immune cells)).
[0054] Also provided herein are methods and materials for using the recombinant hCMV vectors provided herein (e.g., one or more recombinant hCMV vectors, which are designed to infect cells in a mammal to produce cells infected with hCMV vectors in a mammal, which in turn produce and release viral vectors, such as lentiviral vectors that can infect other cells (such as T cells) in vivo and / or can be recognized and internalized by APCs). In some cases, the recombinant hCMV vector viruses provided herein can be used to treat mammals suffering from cancer and / or infectious diseases or at risk of cancer and / or infectious diseases. For example, a method for treating a mammal suffering from cancer and / or infectious diseases may include administering one or more recombinant hCMV viruses provided herein to the mammal. When treating a mammal (e.g., a human) suffering from cancer, one or more recombinant hCMV vectors provided herein may be administered to the mammal to reduce the number of cancer cells in the mammal (e.g., inhibit and / or delay tumor growth) and / or increase the survival rate of the mammal. When treating a mammal (e.g., a human) suffering from an infectious disease, one or more recombinant hCMV vectors provided herein can be administered to the mammal to reduce the number of infected cells in the mammal and / or to reduce the number of pathogens (e.g., pathogens that cause infectious diseases) present in the mammal or to eliminate the pathogens.
[0055] Any suitable mammal (e.g., a mammal suffering from cancer and / or an infectious disease) can be treated as described herein (e.g., by administering one or more recombinant hCMV vectors provided herein). Examples of mammals that can be treated as described herein include, but are not limited to, humans, non-human primates (e.g., monkeys), dogs, cats, horses, cattle, pigs, sheep, mice, and rats. In some cases, one or more recombinant hCMVs provided herein (e.g., one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be administered to humans.
[0056] When using the methods and materials provided herein to treat a cancerous mammal (e.g., a person), the mammal may suffer from any type of cancer. Cancer to be treated as described herein may be a primary cancer or a metastatic cancer. In some cases, the cancer treated as described herein may include one or more solid tumors. In some cases, the cancer treated as described herein may be a blood cancer. Examples of cancers that may be treated as described herein include, but are not limited to, brain cancer (e.g., glioblastoma), B cell lymphoma, ALL, CLL, neuroblastoma, breast cancer, and lung cancer.
[0057] When using the methods and materials provided herein to treat cancerous mammals (for example, people), the method can also include identifying that mammals suffer from cancer. The method of identifying that mammals suffer from cancer includes but is not limited to physical examination, laboratory test (for example blood and / or urine), biopsy, imaging test (for example X-ray, PET / CT, MRI and / or ultrasound), nuclear medicine scanning (for example bone scan), endoscopy and / or gene test. Once identified as suffering from cancer, it can be given to mammals or instruct them to voluntarily give one or more recombinant hCMVs provided herein (for example, one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or the nucleic acid (for example, expression vector) of the recombinant hCMV vectors provided herein that encodes.
[0058] When using the methods and materials provided herein to treat a mammal (e.g., a person) suffering from an infectious disease, the mammal may suffer from any type of cancer or have the risk of suffering from any type of cancer. For example, it is possible to give or instruct a mammal suffering from an infectious disease to voluntarily give one or more recombinant hCMVs (e.g., one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or to encode a nucleic acid (e.g., expression vector) of a recombinant hCMV vector provided herein to reduce the number of pathogens causing infectious diseases in mammals. For example, it is possible to give or instruct a mammal suffering from an infectious disease to voluntarily give one or more recombinant hCMVs (e.g., one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or to encode a nucleic acid (e.g., expression vector) of a recombinant hCMV vector provided herein to reduce or eliminate one or more symptoms of an infectious disease. For example, before exposure to pathogens that can cause infectious diseases, a mammal with a risk of infectious diseases can be given or instructed to self-administer one or more recombinant hCMVs (e.g., one or more recombinant hCMVs designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) to reduce the risk of infectious diseases. In some cases, infectious diseases can be caused by viruses. Examples of infectious diseases that can be treated as described herein include, but are not limited to, viral pneumonia, acquired immunodeficiency syndrome (AIDS) and viral hepatitis.
[0059] When using the method and material treatment provided herein to suffer from a mammal (for example, people) of an infectious disease, the method can also include identifying that a mammal suffers from an infectious disease. The example of the method for identifying that a mammal suffers from an infectious disease includes but is not limited to laboratory tests (for example, laboratory tests of blood samples, urine samples, pharyngeal swab samples, fecal samples and / or spinal puncture samples) to check the specific microorganisms in the sample) and / or imaging scans (for example, X-rays, computed tomography (CT) and magnetic resonance imaging (MRI)). Once identified as suffering from cancer, it can be given to a mammal or instructed to voluntarily give one or more recombinant hCMVs provided herein (for example, one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or encoding nucleic acids (for example, expression vectors) of recombinant hCMV vectors provided herein.
[0060] One or more recombinant hCMVs (e.g., one or more recombinant hCMVs designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APC) or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be administered to mammals by any suitable route (e.g., intravenous, intramuscular, subcutaneous, oral, intranasal, inhaled, transdermal, and parenteral). In some cases, one or more recombinant hCMVs provided herein or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be administered intravenously to mammals (e.g., humans).
[0061] One or more recombinant hCMVs provided herein (e.g., one or more recombinant hCMVs, which are designed to produce and release viral vectors that can infect cells in vivo and / or can be recognized and internalized by APCs) or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be configured into compositions (e.g., pharmaceutical compositions) for administration to mammals (e.g., mammals suffering from cancer and / or infectious diseases). For example, one or more recombinant hCMVs provided herein or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be formulated into pharmaceutically acceptable compositions for administration to mammals suffering from cancer and / or infectious diseases. In some cases, one or more recombinant hCMVs provided herein or nucleic acids encoding recombinant hCMV vectors provided herein (e.g., expression vectors) can be configured together with one or more pharmaceutically acceptable carriers (additives) and / or diluents. Pharmaceutical compositions can be formulated into forms of administration in solid or liquid form, including, but not limited to, sterile solutions, suspensions, sustained-release preparations, tablets, capsules, pills, powders, and granules. Pharmaceutically acceptable carriers, fillers and vehicles that can be used in the pharmaceutical compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.
[0062] The present invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
[0063] Example
[0064] Example 1: Recombinant human cytomegalovirus vector for synthesizing non-herpes virus particles and its use
[0065] This example describes the design of an hCMV vector that can be used for in vivo gene editing of immune cells.
[0066] hCMV BAC Reconstitution System
[0067] Bacterial artificial chromosome (BAC) technology has proven to be a valuable tool for reconstructing herpesviruses, as the DNA genomes of herpesviruses are too large to be cloned into a single plasmid or cosmid. BAC vectors can accommodate DNA sequences up to 300 kb, and hCMV BACs can be created by recombination-mediated integration of the BAC vector into circular hCMV DNA. When combined with the lambda red recombineering system, various types of genetic manipulations, including insertions, deletions, point mutations, and fusions, can be introduced into the hCMV genome. BAC technology and the lambda red recombineering system are used to construct all recombinant viruses and vectors ( Figure 1 ).
[0068] hCMV tropism repair
[0069] hCMV has both endothelialtropic (mediated by gH / gL / UL128-UL131) and non-endothelialtropic (mediated by gH / gL / (gO)) pathways to enter cells. The integrity of these two pathways controls the cell tropism of hCMV. Restoring the function of the gH / gL / UL128-UL131 complex improves cell fusion of hCMV-infected cells and confers tropism for hCMV to infect epithelial cells, endothelial cells, and monocytes (Figure 2), thereby increasing the infectivity of the hCMV vector.
[0070] Construction of synthetic lentiviral hCMV vector: AD169-BAC gag-pol-rev-VSVG / 4070A-LV-EF1a-dtomato (AD169-BAC R5.3 / R5.4)
[0071] Based on hCMV AD169-BAC (a lentiviral vector genome derived from HIV), HIV auxiliary functions (gag, pol and rev) used to package the vector genome and an envelope protein (VSV-G glycoprotein or amphotropic murine leukemia virus 4070A Env envelope protein) were inserted into different genomic sites of AD169-BAC to construct two hCMV vectors AD169-BAC R5.3 (expressing VSVG) and AD169-BAC R5.4 (expressing 4070A) (Figure 3). The inserted HIV-derived lentiviral gene transfer vector genome consists of HIV-LTR, HIV-1Ψ, RRE, cPPT / CTS, a transgene driven by a promoter sequence, and an enhancer sequence.
[0072] The lentiviral production efficiency of the two hCMV vectors was tested in 293T cells, and the AD169-BAC R5.3 vector showed a higher lentiviral yield ( Figure 4 ).
[0073] Optimization of the synthesis efficiency of hCMV vector AD169-BAC R5.4 lentivirus
[0074] To further optimize the efficiency of lentiviral production of hCMV vectors, three regions of the hCMV genome were deleted from the AD169-BAC R5.4 backbone. Deletion of US14-US22 or UL23 increased the production of infectious lentivirus from undetectable to hundreds of transducing units (TU) / mL supernatant ( Figure 5 ). These results suggest that mutations in non-essential genes of hCMV can increase the efficiency of lentiviral production.
[0075] Optimization of lentiviral synthesis efficiency of hCMV vectors AD169-BAC R5.3 and R5.4.
[0076] To further optimize the efficiency of lentiviral production of hCMV vectors, five regions of the hCMV genome were deleted from the AD169-BAC R5.3 and R5.4 backbones. Deletion of US14-US22, US30, UL23, UL83, or UL82 increased the production of infectious lentivirus from undetectable to 10 2 Up to 10 4 Transduction units (TU) / mL supernatant ( Figure 6 ). These results suggest that mutation of non-essential genes of hCMV can further increase the efficiency of lentiviral production.
[0077] Example 2: Genomic sequences of exemplary lentiviral gene transfer vectors
[0078] The genomic sequence of the LV-EF1a-hCD19CAR-T2A-dTomato lentiviral gene transfer vector can be encoded by the recombinant hCMV vector provided herein.
[0079] SEQ ID NO:1
[0080]
[0081] Example 3: Exemplary AD169 UL131 Sequence
[0082] ATGCGCTGTGTCGGGTGTGGCTGTCTGTTTGTCTGTGCGCTGGTGCTGGGTCAGTGCCAGCGGGAAACCGCGGAAAAAAACGATTATTACCGAGTACCGCATTACTGGGACGGTGCTCTCGCGCGCTGCCCGACCAAACCCGTTACAAGTATGTGGAACAGCTCGTGGACCTCACGTTGAACTACCACTACGATGCGAGCCACGGCTTGGACAACTTTGACGTGCTCAAGAGGTGAGGGTACGCG CTAAAGGTGCATGACAACGGGAAGGTAAGGGCGAACGGGTAACGGCTAAGTAACCGCATGGGGTATGAAATGACGTTTGGAACCTGTGCTTGCAGAATCAACGTGACCGAGGTGTCGTTGCTCA TCAGCGACTTTAGACGTCAGAACCGTCGCGGCGGCACCAACAAAAGGACCACGTTCAACGCCGCCGGTTCCGCTGGCGCCACACGCCCGGAGCCTCGAGTTCAGCGTGGCGGCTCTTTGCCAACTAG
[0083] Example 4: In vivo generation of CAR T cells
[0084] A recombinant hCMV vector engineered by replacing a promoter with a T cell-specific promoter, which can produce and release a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) that can infect T cells in vivo and can drive the expression of CAR in infected T cells in a mammal (e.g., a human) to generate CAR in the mammal + T cells. For example, Figure 3A The nucleic acid encoding the dTomato polypeptide is replaced by a transgene encoding the CD19 CAR, and as Figure 3A The EF1a promoter is replaced by a T cell specific promoter (eg, CD3D promoter) as shown.
[0085] Example 5: Construction of an inducible hCMV vector capable of synthesizing lentivirus
[0086] Based on hCMV AD169-BAC, an hCMV vector capable of encoding and driving lentiviral synthesis in a drug-controllable manner was constructed. The following steps were used to generate an hCMV vector capable of inducing lentiviral synthesis.
[0087] The nucleic acid containing pRSV-tTA-pTight-rev was inserted between hCMV IRS1 and US1 by homologous recombination.
[0088] Nucleic acid containing pTight-VSV-F-SV40pA-ZeoR-pEM7 was inserted in front of the pRSV-tTA-pTight-rev cassette of the hCMV vector.
[0089] Nucleic acid containing pCMV-gag-pol-β-globin poly A was inserted between hCMV UL25 and UL26.
[0090] The nucleic acid containing pRSV truncated 5'UTR(HIV)-HIV-1Ψ-RRE-cPPT / CTS-pCD43-CD19CAR-dTomato-WPRE-5'UTR(ΔU3)-SV40pA-pA mp-AmpR was inserted between hCMV US32 and US33A.
[0091] Figure 7 Schematic diagram showing the construction of hCMV vectors that encode and drive lentiviral synthesis in a drug-controllable manner.
[0092] Example 6: Generation of inducible hCMV vectors capable of synthesizing lentivirus
[0093] In vitro production of high titer recombinant hCMV vectors capable of producing and releasing viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)). Fibroblasts (e.g., human fibroblasts (such as MRC-5 or WI-38 cells)) are infected with recombinant hCMV vectors that can produce and release viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)) in the absence of specific drugs (e.g., in the absence of tetracycline or doxycycline), and the specific drugs (e.g., tetracycline or doxycycline) are administered to inhibit the synthesis of viral vectors. For example, Figure 7 As shown, fibroblasts (e.g., human fibroblasts (such as MRC-5 or WI-38 cells)) are infected with hCMV vectors, and tetracycline is administered to inhibit the synthesis of viral vectors. The recombinant hCMV vector is replicated by infected cells to generate high titer recombinant hCMV. In some cases, the recombinant hCMV vector is purified from cell culture.
[0094] Example 7: In vivo generation of CAR T cells
[0095] A recombinant hCMV vector capable of producing and releasing a viral vector (e.g., a heterologous viral gene transfer vector such as a lentiviral vector) in the absence of a particular drug (e.g., in the absence of tetracycline or doxycycline) is administered to a mammal and infects cells within the mammal. For example, administration to a mammal Figure 7 hCMV vector shown. Cells infected with the hCMV vector produce and release viral vectors (e.g., heterologous viral gene transfer vectors (such as lentiviral vectors)), which can infect T cells in vivo and can express CAR to generate CAR+T cells in mammals.
[0096] Example 8: Treatment of cancer
[0097] One or more recombinant hCMV vectors are given to a person identified as having CD19-positive cancer, which is designed to produce and release a viral vector (e.g., a heterologous viral gene transfer vector (such as a lentiviral vector)) that can express CD19 CAR and can infect cells in vivo. The recombinant hCMV vector can infect cells in the human body, so that the viral vector produced and released by the recombinant hCMV vector can infect T cells in the human body and can express CD19 CAR to generate CD19-CAR T cells in the human body. The CD19-CAR T cells generated in vivo can target and destroy CD19-positive cancer cells in the human body.
[0098] Example 9: Treatment of AIDS
[0099] One or more recombinant hCMV vectors are given to people identified as having AIDS, which are designed to produce and release HIV-derived lentiviral vectors. Recombinant hCMV vectors can infect cells in the human body, so that the HIV-derived lentiviral vectors produced and released by the recombinant hCMV vectors are internalized by APCs in vivo, so that one or more polypeptide vectors derived from HIV lentivirus are presented as antigens to T cells (e.g., naive T cells) in the human body to induce an immune response to HIV particles present in the human body. The immune response to HIV particles present in the human body can reduce or eliminate one or more symptoms of AIDS.
[0100] Example 10: Prevention of AIDS
[0101] One or more recombinant hCMV vectors are given to people who are determined to be HIV positive or have HIV exposure risk, which are designed to produce and release HIV-derived lentiviral vectors. Recombinant hCMV vectors can infect cells in the human body, so that the HIV-derived lentiviral vectors produced and released by the recombinant hCMV vectors are internalized by APCs in vivo, so that one or more polypeptide vectors derived from HIV lentivirus are presented as antigens to T cells (e.g., naive T cells) in the human body to start the T cells. In the presence of HIV particles, the activated T cells induce an immune response to HIV particles present in the human body. The immune response to HIV particles present in the human body can prevent the development of AIDS.
[0102] Other Implementations
[0103] It should be understood that although the invention has been described in conjunction with specific embodiments, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and improvements are within the scope of the claims.
Claims
1. A recombinant human cytomegalovirus (hCMV) vector capable of infecting mammalian cells, wherein the hCMV vector comprises a heterologous nucleic acid encoding (i) a heterologous viral gene transfer vector genome and (ii) one or more auxiliary polypeptides for amplifying the heterologous viral gene transfer vector genome and packaging it into infectious vector particles, wherein the cells infected with the hCMV vector produce and release the infectious vector particles comprising the gene transfer vector genome.
2. The hCMV vector of claim 1, wherein in the cell, the hCMV vector is replicative.
3. The hCMV vector according to any one of claims 1-2, wherein the hCMV vector lacks a nucleic acid encoding a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide or miR-UL148D.
4. The hCMV vector according to any one of claims 1-2, wherein the hCMV vector lacks a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide or miR-UL148D.
5. The hCMV vector according to any one of claims 1 to 4, wherein the hCMV vector is derived from hCMV AD169 strain or hCMV Merlin strain.
6. The hCMV vector of any one of claims 1 to 5, wherein the hCMV vector lacks a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
7. The hCMV vector of any one of claims 1-5, wherein the hCMV vector lacks a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
8. The hCMV vector according to any one of claims 1 to 7, wherein the cell is a fibroblast, an epithelial cell, an endothelial cell, a monocyte or a glial cell.
9. The hCMV vector of any one of claims 1-8, wherein the viral gene transfer vector genome is a lentiviral vector genome, a retroviral vector genome, an adeno-associated virus (AAV) vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome.
10. The hCMV vector of any one of claims 1-9, wherein the viral gene transfer vector genome comprises a nucleic acid sequence encoding a therapeutic polypeptide or an antigen receptor polypeptide, wherein the infectious vector particles comprising the gene transfer vector genome can infect immune cells in the mammal, and wherein the infected immune cells direct the expression of the therapeutic polypeptide or the antigen receptor polypeptide.
11. The hCMV vector of claim 10, wherein the viral gene transfer vector genome comprises a nucleic acid sequence encoding the therapeutic polypeptide.
12. The hCMV vector according to claim 11, wherein the therapeutic polypeptide is a chemokine, a cytokine, an anti-PD1 antibody, an anti-PDL-1 antibody, an anti-CTLA-4 antibody or a CD47 polypeptide.
13. The hCMV vector of claim 10, wherein the viral gene transfer vector genome comprises a nucleic acid sequence encoding the antigen receptor polypeptide.
14. The hCMV vector of claim 13, wherein the antigen receptor polypeptide is a chimeric antigen receptor (CAR) polypeptide.
15. The hCMV vector of claim 14, wherein the CAR polypeptide is an anti-CD19 CAR.
16. The hCMV vector according to any one of claims 10-15, wherein the immune cell is a T cell, a natural killer (NK) cell or a natural killer T (NKT) cell.
17. The hCMV vector of any one of claims 10-16, wherein the viral gene transfer vector is replication-defective in the infected immune cells.
18. The hCMV vector of any one of claims 1-17, wherein the viral gene transfer vector genome comprises one or more packaging elements selected from the following group: 5' long terminal repeat (LTR), 3' LTR, Ψ (psi) element, Rev response element (RRE) and central polypurine tract / central termination sequence (cPPT / CTS).
19. The hCMV vector of any one of claims 1-18, wherein the nucleic acid encoding one or more auxiliary polypeptides comprises a nucleic acid encoding an envelope polypeptide selected from the group consisting of a vesicular stomatitis virus G (VSV G) polypeptide and a murine leukemia virus (MLV) 4070A polypeptide.
20. The hCMV vector of claim 19, wherein the released viral gene transfer vector comprises the envelope polypeptide.
21. A method for treating a mammal suffering from cancer, wherein the method comprises administering a recombinant hCMV vector to the mammal, wherein the hCMV vector is capable of infecting cells of the mammal, wherein the hCMV comprises a heterologous nucleic acid encoding: (i) a heterologous viral gene transfer vector genome comprising a nucleic acid sequence encoding an antigen receptor polypeptide that targets a cancer antigen of the cancer; (ii) one or more auxiliary polypeptides for amplifying the heterologous viral gene transfer vector genome and packaging it into infectious vector particles, and wherein the released infectious vector particles are capable of infecting immune cells in the mammal and directing the infected immune cells to express the antigen receptor polypeptide, and wherein the infected immune cells that express the antigen receptor reduce the number of cancer cells in the mammal.
22. The method of claim 21, wherein the mammal is a human.
23. The method of any one of claims 21-22, wherein the cancer is selected from the group consisting of brain cancer, B-cell lymphoma, ALL, CLL, neuroblastoma, breast cancer, and lung cancer.
24. The method of any one of claims 21-24, wherein the cancer antigen is selected from the following group: cluster of differentiation 19 (CD19), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, mucin 1 (MUC-1), epithelial tumor antigen (ETA), melanoma-associated antigen (MAGE), human epidermal growth factor receptor 2 (HER2), biotin, EGFRvIII, CD171 and mesothelin.
25. The method of any one of claims 21-25, wherein in the cell, the hCMV vector is replicating.
26. The method of any one of claims 21-26, wherein the hCMV vector lacks a nucleic acid encoding a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide, or miR-UL148D.
27. The hCMV vector of any one of claims 21-26, wherein the hCMV vector lacks a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide, or miR-UL148D.
28. The method according to any one of claims 21-28, wherein the hCMV vector is derived from the hCMV AD169 strain or the hCMV Merlin strain.
29. The method of any one of claims 21-29, wherein the hCMV vector lacks a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
30. The method of any one of claims 21-29, wherein the hCMV vector lacks a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
31. The method of any one of claims 21-30, wherein the cell is a fibroblast, an epithelial cell, an endothelial cell, a monocyte, or a glial cell.
32. The method of any one of claims 21-31, wherein the viral gene transfer vector genome is a lentiviral vector genome, a retroviral vector genome, an AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome.
33. The method of any one of claims 21-32, wherein the viral gene transfer vector comprises a nucleic acid encoding one or more packaging elements selected from the group consisting of a 5' LTR, a 3' LTR, a Ψ (psi) element, a RRE, and a cPPT / CTS.
34. The method of any one of claims 21-33, wherein the nucleic acid encoding one or more accessory polypeptides comprises a nucleic acid encoding an envelope polypeptide selected from the group consisting of: VSV G protein or MLV 4070A protein.
35. The method of claim 34, wherein the released viral gene transfer vector comprises the envelope polypeptide.
36. A method for treating a mammal suffering from an infectious disease, wherein the method comprises administering a recombinant hCMV vector to the mammal, wherein the hCMV vector is capable of infecting cells of the mammal, wherein the hCMV comprises a heterologous nucleic acid encoding: (i) a heterologous viral gene transfer vector genome derived from a virus that causes an infectious disease; (ii) one or more auxiliary polypeptides for amplifying the heterologous viral gene transfer vector genome and packaging it into infectious vector particles, wherein the cells infected with the hCMV vector produce and release infectious vector particles comprising the gene transfer vector genome, and wherein the infectious vector particles are recognized by antigen presenting cells (APCs) in the mammal, such that the APCs present antigens from the viral gene transfer vector to T cells in the mammal, and wherein the T cells recognize and destroy the virus that causes the infectious disease in the mammal.
37. The method of claim 36, wherein the mammal is a human.
38. The method according to any one of claims 36-37, wherein the infectious disease is selected from the group consisting of viral pneumonia, acquired immunodeficiency syndrome, and viral hepatitis.
39. The method of any one of claims 36-38, wherein in the cell, the hCMV vector is replicating.
40. The method of any one of claims 36-39, wherein the hCMV vector lacks a nucleic acid encoding a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide, or miR-UL148D.
41. The hCMV vector of any one of claims 36-39, wherein the hCMV vector lacks a UL138 polypeptide, a UL144 polypeptide, a UL146 polypeptide, a UL147 polypeptide, or miR-UL148D.
42. The method according to any one of claims 36-41, wherein the hCMV vector is derived from the hCMV AD169 strain or the hCMV Merlin strain.
43. The method of any one of claims 36-42, wherein the hCMV vector lacks a nucleic acid encoding a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
44. The method of any one of claims 36-42, wherein the hCMV vector lacks a UL23 polypeptide, a US1 polypeptide, a US2 polypeptide, a US3 polypeptide, a US4 polypeptide, a US5 polypeptide, a US6 polypeptide, a US7 polypeptide, a US8 polypeptide, a US9 polypeptide, a US10 polypeptide, a US11 polypeptide, a US14 polypeptide, a US15 polypeptide, a US16 polypeptide, a US17 polypeptide, a US18 polypeptide, a US19 polypeptide, a US20 polypeptide, a US21 polypeptide, a US22 polypeptide, a US30 polypeptide, a UL82 polypeptide, or a UL83 polypeptide.
45. The method of any one of claims 36-44, wherein the cell is a fibroblast, an epithelial cell, an endothelial cell, a monocyte, or a glial cell.
46. The method of any one of claims 36-45, wherein the viral gene transfer vector genome is a lentiviral vector genome, a retroviral vector genome, an AAV vector genome, a picornavirus vector genome, a rhabdovirus vector genome, or a coronavirus vector genome.
47. The method of any one of claims 36-46, wherein the viral gene transfer vector genome comprises a nucleic acid encoding one or more packaging elements selected from the group consisting of a 5' LTR, a 3' LTR, a Ψ (psi) element, a RRE, and a cPPT / CTS.
48. The method of any one of claims 36-47, wherein the nucleic acid encoding one or more accessory polypeptides comprises a nucleic acid encoding an envelope polypeptide selected from the group consisting of: VSV G protein or MLV 4070A protein.
49. The method of claim 48, wherein the released viral gene transfer vector comprises the envelope polypeptide.
50. Use of a composition comprising the recombinant hCMV according to any one of claims 1 to 20 in the treatment of cancer or infectious diseases.
51. The recombinant hCMV according to any one of claims 1-20 for use as a medicament for the treatment of cancer or infectious diseases.
52. The recombinant hCMV according to any one of claims 1-20, for use in treating cancer or an infectious disease.
